Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C

Molecular Medicine Reports

Volumn 6, Issue 2, 2012, Pages 259-264

  Imakiire, Kazuyuki ^a   Uto, Hirofumi ^a   Sato, Yuko ^b   Sasaki, Fumisato ^a   Mawatari, Seiichi ^a   Ido, Akio ^a   Shimoda, Kazuya ^c   Hayashi, Katsuhiro ^d   Stuver, Sherri O ^e   Ito, Yoshito ^f   Okanoue, Takeshi ^g   Tsubouchi, Hirohito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Miyazaki Prefectural Industrial Support Foundation   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

C4 fragment; Complement component C4a; Hepatitis C virus; Persistent normal alanine aminotransferase; Serum proteomics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; COMPLEMENT COMPONENT C4A; DECARBOXYPROTHROMBIN; FERRITIN; GELATINASE A; HYALURONIC ACID; IMMUNOGLOBULIN; PLASMA PROTEIN; VIRUS ANTIGEN;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOCYTE COUNT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; THROMBOCYTE COUNT; VIRUS CARRIER; VIRUS CORE;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARRIER STATE; CASE-CONTROL STUDIES; COHORT STUDIES; COMPLEMENT C4A; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PROTEOMICS; RNA, VIRAL; SEROLOGIC TESTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VIRAL CORE PROTEINS;

HEPATITIS C VIRUS;

EID: 84863458516     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.924     Document Type: Article

References (29)

1. No authors listed. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35-47, 1999.
2. Lavanchy D: The global burden of hepatitis C. Liver Int 29: 74-81, 2009.
3. Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, Nicosia A, Vecchione R, Mura VL, Masarone M and Torella R: Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 13: 290-296, 2006.
4. Uto H, Kurogi J, Takahama Y, Kusumoto K, Hayashi K, Ido A, Kohara M, Stuver SO, Moriuchi A, Hasegawa S, Oketani M and Tsubouchi H: Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan. J Gastroenterol 42: 673-680, 2007. (Pubitemid 47278693)
5. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, Sasso FC and Torella R: Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118: 760-764, 2000. (Pubitemid 30171625)
6. Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H and Stuver SO: Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 119: 192-195, 2006.
7. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K and Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055, 1995.
8. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N and Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32: 228-232, 2000. (Pubitemid 30614654)
9. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M and Kumada H: Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 79: 1485-1490, 2007. (Pubitemid 47328737)
10. Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO and Tsubouchi H: Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 45: 948-956, 2007. (Pubitemid 46631563)
11. Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver SO and Tsubouchi H: The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 45: 459-467, 2010.
12. Uto H, Kanmura S, Takami Y and Tsubouchi H: Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 8: 70, 2010.
13. Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, Yasui K, Minami M and Itoh Y: A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43: 599-605, 2005. (Pubitemid 41253226)
14. Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M and Tsubouchi H: Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a communitybased cohort study. Hepatology 50: 393-399, 2009.
15. Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, Hubert Gruener N, Houghton M and Pape GR: Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 32: 597-603, 2000.
16. Itose I, Kanto T, Kakita N, Takebe S, Inoue M, Higashitani K, Miyazaki M, Miyatake H, Sakakibara M, Hiramatsu N, Takehara T, Kasahara A and Hayashi N: Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat 16: 844-852, 2009.
17. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W and Zhang X: Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 6: 235-244, 2009.
18. Ambrus G, Gál P, Kojima M, Szilágyi K, Balczer J, Antal J, Gráf L, Laich A, Moffatt BE, Schwaeble W, Sim RB and Závodszky P: Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol 170: 1374-1382, 2003. (Pubitemid 36139504)
19. Poljacki M, Gajinov Z, Ivkov M, Matić M and Golusin Z: Skin diseases and hepatitis virus C infection. Med Pregl 53: 141-145, 2000.
20. Dumestre-Perard C, Ponard D, Drouet C, Leroy V, Zarski JP, Dutertre N and Colomb MG: Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin Exp Immunol 127: 131-136, 2002. (Pubitemid 34155468)
21. Banerjee A, Mazumdar B, Meyer K, Di Bisceglie AM, Ray RB and Ray R: Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol 85: 4157-4166, 2011.
22. Wallis R, Dodds AW, Mitchell DA, Sim RB, Reid KB and Schwaeble WJ: Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway. J Biol Chem 282: 7844-7851, 2007. (Pubitemid 47093568)
23. Pfeifer PH, Brems JJ, Brunson M and Hugli TE: Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. Immunopharmacology 46: 163-174, 2000. (Pubitemid 30019257)
24. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS and Atkinson JP. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 207: 793-806, 2010.
25. Zapata R: Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. Ann Hepatol 9 suppl: 72-79, 2010.
26. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F and Lardelli P; PEGASYS Study NR16071 Investigator Group: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127: 1724-1732, 2004. (Pubitemid 39575851)
27. Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K and Izumi N: Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. J Gastroenterol 46: 1111-1119, 2011.
28. Puoti C: Hepatitis C virus with normal transaminase levels. Dig Dis 25: 277-278, 2007.
29. Izumi N, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N and Kudo M: Management of hepatitis C: report of the consensus meeting at the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 40: 347-368, 2010.